16234-15-4

Basic information

• Product Name: 2-Chloro-4-(morpholin-4-yl)thieno[3,2-d]pyrimidine
• Synonyms: 2-Chloro-4-(morpholin-4-yl)thieno[3,2-d]pyrimidine;2-Chloro-4-(4-morpholinyl)thieno[3,2-d]pyrimidine;4-(2-chlorothieno[3,2-d]pyrimidin-4-yl)morpholine;2-chloro-4-(4-Morpholinyl)-;2-chloro-4-Morpholinothieno[3,2-d]pyriMidine;Thieno[3,2-d]pyriMidine, 2-chloro-4-(4-Morpholinyl)-;2-Chloro-4-(morpholin-4-yl)thieno[3,2-d]pyrimidine-4;4-(2-Chlorothieno[3,2-d]pyrimidin-4-yl)
• CAS NO: 16234-15-4
• Molecular Formula: C₁₀H₁₀ClN₃OS
• Molecular Weight: 255.72
• Product Categories: Heterocycle-Pyrimidine series
• Mol File: 16234-15-4.mol
• Article Data: 41

Chemical Properties

• Boiling Point: 393.748 °C at 760 mmHg
• Flash Point: 191.932 °C
• Appearance: /
• Density: 1.463
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.671
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 3.82±0.40(Predicted)
• CAS DataBase Reference: 2-Chloro-4-(morpholin-4-yl)thieno[3,2-d]pyrimidine(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Chloro-4-(morpholin-4-yl)thieno[3,2-d]pyrimidine(16234-15-4)
• EPA Substance Registry System: 2-Chloro-4-(morpholin-4-yl)thieno[3,2-d]pyrimidine(16234-15-4)

Safety Data

• Hazardous Substances Data: 16234-15-4(Hazardous Substances Data)

Usage

General Description

2-Chloro-4-(morpholin-4-yl)thieno[3,2-d]pyrimidine is a complex organic compound that includes chlorine, nitrogen, and sulfur in a pyrimidine and thieno structure. Its formula is C9H8ClN3OS. As a compound, it is used in various research and development processes, particularly within the pharmaceutical industry. It potentially serves as an intermediate in the synthesis of certain drugs or chemical compounds. It's a relatively specialized chemical and typically requires specific handling and storage conditions due to its reactivity. MIT undergraduates don't generally use this chemical in their standard laboratory procedures.

InChI:InChI=1/C10H10ClN3OS/c11-10-12-7-1-6-16-8(7)9(13-10)14-2-4-15-5-3-14/h1,6H,2-5H2

Upstream product

• 110-91-8 morpholine 
• 16234-14-3 2,4-dichlorothieno[3,2-d]pyrimidine 
• 16233-51-5 1H-thieno[3,2-d]pyrimidine-2,4-dione 
• 22288-78-4 Methyl 3-aminothiophene-2-carboxylate 
• 16233-51-5 2,4-dihydroxythieno[3,2-d]pyrimidine 

Downstream Products

• 956034-15-4 4-(2-chloro-6-iodothieno[3,2-d]pyrimidin-4-yl)morpholine 
• 885618-31-5 2-chloro-4-morpholinothieno[3,2-d]pyrimidine-6-carbaldehyde 
• 956392-90-8 (2-chloro-4-morpholin-4-yl-thieno[3,2-d]pyrimidin-6-yl)-(4-methylsulfanyl-phenyl)-methanol 
• 885698-97-5 2-chloro-4-morpholinylthiophene[3,2-d]pyrimidine-6-methanol 
• 1058193-95-5 2-methyl-3-(4-morpholin-4-yl-thieno[3,2-d]pyrimidin-2-yl)phenylamine 
• 956390-23-1 2-methyl-5-(4-morpholin-4-yl-thieno[3,2-d]pyrimidin-2-yl)phenylamine 
• 885616-90-0 4-morpholin-4-yl-2-[3-(1,1,2,2-tetramethylpropylsilanyloxy)phenyl]thieno[3,2-d]pyrimidine 
• 955979-15-4 1-(2-chloro-4-morpholinothieno[3,2-d]pyrimidin-6-yl)-N-methylmethanamine 
• 885617-10-7 tert-butyl 4-((2-(3-hydroxyphenyl)-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)piperazine-1-carboxylate 
• 1276109-64-8 tert-butyl 4-(2-(3-hydroxyphenyl)-4-morpholinothieno[3,2-d]pyrimidin-6-yl)-5,6-dihydropyridine-1(2H)-carboxylate 
• 1276107-33-5 N-(4-acrylamidophenethyl)-2-(1H-indazol-4-yl)-4-morpholinothieno[3,2-d]pyrimidine-6-carboxamide 
• 1276109-92-2 tert-butyl 3-(2-acrylamido-5-(4-(2-(3-hydroxyphenyl)-4-morpholinothieno[3,2-d]pyrimidin-6-yl)-1,2,3,6-tetrahydropyridine-1-carbonyl)phenoxy)propylcarbamate 
• 1276109-94-4 N-(2-(3-aminopropoxy)-4-(4-(2-(3-hydroxyphenyl)-4-morpholinothieno[3,2-d]pyrimidin-6-yl)-1,2,3,6-tetrahydropyridine-1-carbonyl)phenyl)acrylamide trifluoroacetate 
• 1276109-47-7 N₁-(3-(2-acrylamido-5-(4-(2-(3-hydroxyphenyl)-4-morpholinothieno[3,2-d]pyrimidin-6-yl)-1,2,3,6-tetrahydropyridine-1-carbonyl)phenoxy)propyl)-N₅-(15-oxo-19-((3aR,4R,6aS)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)-4,7,10-trioxa-14-azanonadecyl)glutaramide 

Relevant articles and documents

PARP-1/PI3K double-target inhibitor or pharmaceutically acceptable salt thereof, preparation method and application thereof

The invention discloses a PARP-1/PI3K double-target inhibitor or a pharmaceutically acceptable salt thereof, a preparation method and application thereof. According to the invention, the single active component can play a dual inhibition role on PARP-1 and PI3K, so that the dosage is reduced, the treatment effect is improved, and the toxic and side effects are reduced; and the dual inhibition effect on PARP-1 and PI3K is significant, the IC50 value of each target does not exceed 1.0 [mu]M, and the drug using the PARP-1/PI3K double-target inhibitor as the active component can be used for treating a variety of cancers or tumors related to PARP-1 and/or PI3K.

Piperazinone substitute or derivative thereof, preparation method and application thereof, and pharmaceutical composition

The invention relates to a piperazinone substitute or a derivative thereof, a preparation method and application thereof, and a pharmaceutical composition, and belongs to the technical field of anti-tumor drugs. The invention designs a piperazinone substituted heterocyclic small molecule compound. The compound shows good affinity to PI3K delta, and the compound can down-regulate the activity of a PI3K pathway in tumor cells, so that the compound shows good inhibitory activity to PI3K delta dependent tumors, and is expected to be used as one of components of a pharmaceutical preparation for treatment of different tumors. The preparation method of the piperazinone substitute is simple and convenient, and the yield is relatively high.

COMBINATION THERAPY WITH A PHOSPHOINOSITIDE 3-KINASE INHIBITOR WITH A ZINC BINDING MOIETY

The invention provides a method of treating cancer in a subject in need thereof, comprising administering to the subject: (a) a compound of Formula I: or a pharmaceutically acceptable salt thereof, wherein R is hydrogen or an acyl group; and (b) a PD-1 signaling inhibitor; wherein the compound of Formula I or pharmaceutically acceptable salt thereof and the PD-1 signaling inhibitor are administered in amounts which in combination are therapeutically effective. The invention further provides a pharmaceutical composition comprising a compound of Formula I or a pharmaceutically acceptable salt thereof, a PD-1 signaling inhibitor and a pharmaceutically acceptable carrier or excipient.